Nobel Prize in Chemistry 2020 Awarded to Charpentier and Doudna for CRISPR-Cas9 Gene Editing

Stockholm, Sweden · 7 October 2020

The Royal Swedish Academy of Sciences announced on 7 October 2020 that the Nobel Prize in Chemistry would be awarded to Emmanuelle Charpentier and Jennifer A. Doudna "for the development of a method for genome editing." Their discovery of the CRISPR-Cas9 genetic scissors — a technology that allows researchers to alter the DNA of animals, plants, and microorganisms with extraordinary precision — has been described as a tool for rewriting the code of life.

The Origins of a Revolutionary Tool

The story of CRISPR-Cas9 begins not in a gene-editing laboratory but in the study of bacterial immune systems. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) was first described in 1987 by Japanese researchers who observed unusual repeated sequences in the genome of Escherichia coli. For years, the function of these sequences remained a mystery.

In the 2000s, scientists began to understand that CRISPR and its associated Cas proteins constitute a bacterial defense mechanism against viral infections — a kind of adaptive immune system that allows bacteria to "remember" and destroy invading viruses by cutting their DNA.

The critical breakthrough came from Emmanuelle Charpentier's research on Streptococcus pyogenes, the bacterium responsible for a range of human infections from strep throat to necrotizing fasciitis. In 2011, Charpentier published the discovery of a previously unknown molecule called tracrRNA, which plays a key role in the CRISPR-Cas9 system by activating the mechanism that enables the bacteria to cut viral DNA.

A Collaboration That Changed Biology

Later in 2011, Charpentier initiated a collaboration with Jennifer Doudna, a biochemist at the University of California, Berkeley, whose expertise in RNA structure and function complemented Charpentier's microbiological findings. Together, they set out to understand how the CRISPR-Cas9 system worked in molecular detail.

In a landmark paper published in Science in August 2012, Charpentier and Doudna demonstrated that the CRISPR-Cas9 system could be reprogrammed to cut any DNA molecule at a predetermined site. They showed that by designing a guide RNA molecule to match a specific DNA sequence, they could direct the Cas9 enzyme to make a precise cut at that location. This simple but powerful insight transformed a bacterial immune mechanism into a versatile gene-editing tool.

How CRISPR-Cas9 Works

The elegance of CRISPR-Cas9 lies in its simplicity. The system consists of two components:

Once the DNA is cut, the cell's natural repair mechanisms take over. Scientists can exploit these repair pathways either to disrupt a gene (by allowing error-prone repair to introduce mutations) or to insert a new sequence (by providing a repair template). This dual capability makes CRISPR-Cas9 both a knock-out and a knock-in tool.

Applications and Impact

Since 2012, CRISPR-Cas9 has spread through the life sciences like wildfire. The Nobel Committee highlighted several areas where the technology has already had transformative impact:

• Cancer therapies: CRISPR is being used to engineer immune cells (CAR-T therapy) to better recognize and attack tumors. Clinical trials using CRISPR-edited cells in cancer patients began in 2016.
• Inherited diseases: The first CRISPR-based therapy to treat sickle cell disease and beta-thalassemia — developed by Vertex Pharmaceuticals and CRISPR Therapeutics — received regulatory approval in late 2023.
• Agriculture: CRISPR is being used to create crops with improved yield, drought resistance, and nutritional content, without introducing foreign DNA.
• Basic research: The tool has democratized genetic research, allowing laboratories that previously lacked gene-editing capabilities to study gene function across organisms.

"There is enormous power in this genetic tool, which affects us all. It has not only revolutionised basic science, but also resulted in innovative crops and will lead to ground-breaking new medical treatments."

— Claes Gustafsson, Chair of the Nobel Committee for Chemistry, 7 October 2020

A Complex Legacy

The Nobel Prize announcement also reignited a long-running patent dispute over CRISPR-Cas9. The Broad Institute of MIT and Harvard, working with researcher Feng Zhang, had filed patents on the use of CRISPR-Cas9 in eukaryotic cells, while Doudna's group at Berkeley and Charpentier at the University of Vienna filed earlier patents on the fundamental technology. The US Patent Trial and Appeal Board ruled in 2022 that the Broad Institute's patents would stand for use in eukaryotic cells, while Berkeley's patents cover broader applications. The dispute remains a landmark case in biotechnology intellectual property.

The Laureates

Emmanuelle Charpentier (born 1968) is a French microbiologist and geneticist. At the time of the award, she was director of the Max Planck Unit for the Science of Pathogens in Berlin. Her career took her through institutions in the United States, Austria, Sweden, and Germany before she established her own research unit.

Jennifer A. Doudna (born 1964) is an American biochemist at the University of California, Berkeley, and a Howard Hughes Medical Institute investigator. She is also a co-founder of several biotechnology companies, including Editas Medicine, Intellia Therapeutics, and Caribou Biosciences, and has been a leading voice in the ethical debate over genome editing.

A New Era in the Life Sciences

The 2020 Nobel Prize in Chemistry recognized not just a single discovery but the opening of an entirely new era in the life sciences. CRISPR-Cas9 has made genome editing faster, cheaper, and more precise than any previous technology, and its applications continue to expand. From correcting disease-causing mutations to engineering crops that can withstand climate change, the genetic scissors developed by Charpentier and Doudna have become an indispensable tool in the global scientific toolkit.

The award also sent a powerful message about representation in science. As Charpentier noted in her Nobel interview: "My hope is that this will provide a positive message specifically to young girls who would like to follow the path of science, and to show them that women in science can also have an impact through the work that they are doing."

---

Sources:

• Nobel Prize in Chemistry 2020 press release, Royal Swedish Academy of Sciences (nobelprize.org)
• Nobel Prize in Chemistry 2020 popular science background (nobelprize.org)
• Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity." Science, 17 August 2012
• UNESCO statement on 2020 Nobel Prize in Chemistry (unesco.org)